Genolier Swiss Medical Network (GSMN) announces successful completion of capital increase

Genolier Swiss Medical Network (GSMN)  / Key word(s): Capital Increase/Capital Increase

21.12.2011 07:15

Release of an ad hoc announcement pursuant to Art. 53 KR

The group of private clinics Genolier Swiss Medical Network SA (GSMN)
offered its shareholders in a capital increase out of GSMN's authorized
capital the opportunity to subscribe one new registered share at a
subscription price of CHF 19 for six existing registered shares. 84.95% of
the subscription rights were exercised. M.R.S.I. supported the transaction
and subscribed for 870'562 new registered shares for a value of
approximately 16.5 million. In total, GSMN has issued 877'879 new
registered shares. The gross proceeds amounts to approximately CHF 16.7
million. Trading in the new registered shares on the SIX Swiss Exchange is
expected to commence on 23 December 2011. Delivery of the new registered
shares against payment of the subscription price should occur on 27
December 2011.

Genolier Swiss Medical Network SA (GSMN) is the second largest network of
private clinics in Switzerland. Its growth strategy focuses on the creation
of a national network through the acquisition of clinics and the
restructuring of their operations. GSMN's main aim is to offer first class
hospital care to Swiss and foreign patients. The distinctive features of
GSMN include its high quality services, its brand value, a pleasant working
environment and an experienced management team with an entrepreneurial
approach. On 1 January 2012, GSMN will operate 10 private establishments in
Switzerland (Clinique de Genolier, Clinique de Montchoisi, Clinique
Valmont, Clinique Générale, Centre médico-chirurgical des Eaux-Vives, Ars
Medica Clinic, Clinica Sant'Anna, Privatklinik Bethanien, Privatklinik
Lindberg und Privatklinik Obach), with more than 1'000 practising
physicians and 1'600 employees. The Group is listed on the Domestic
Standard of the SIX Swiss Exchange (GSMN:SW).

This document does neither constitute an offer to buy or to subscribe for
securities of Genolier Swiss Medical Network SA nor a prospectus within the
meaning of applicable Swiss law. Investors should make their decision to
buy or to subscribe to securities solely based on the official offering and
listing prospectus published by Genolier Swiss Medical Network SA and
available free of charge from Bank Vontobel AG (telephone: +41 58 283 70
03, facsimile: +41 58 283 70 75 or email:
Investors are furthermore advised to consult their bank or financial
adviser before making any investment decision.

This document does not contain or constitute an offer to sell or a
solicitation of any offer to buy securities in the United States or in any
other jurisdiction in which such offer or solicitation is not authorised or
to any person to whom it is unlawful to make an offer or solicitation. The
securities of Genolier Swiss Medical Network SA have not been and will not
be registered under the United States securities laws and may not be
offered or sold in the United States absent registration or an exemption
from registration under the U.S. Securities Act of 1933, as amended.
Neither Genolier Swiss Medical Network SA nor its shareholders intend to
register any portion of the offering in the United States or conduct a
public offering of securities in the United States.

For further information, please contact:
Séverine Van der Schueren
General Secretary, GSMN
Tel. +41 22 366 99 87

21.12.2011 News transmitted by EquityStory AG. 
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital 
market and press releases.
The EquityStory Group distributes authentic and real-time financial news 
for over 1'300 listed companies. 
The Swiss news archive can be found at

This website uses cookies.
Please see our Privacy Guidelines for further details.